Jan 25, 2024
https://visiblealpha.com/wp-content/uploads/2024/01/Three-Key-Questions-About-Netflix-NFLX-Q4-2023-Earnings.jpg
628
1200
Melissa Otto, CFA
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Melissa Otto, CFA2024-01-25 14:01:352024-01-25 19:39:13Three Key Questions About Netflix (NFLX) Q4 2023 EarningsJan 18, 2024
https://visiblealpha.com/wp-content/uploads/2024/01/FDA-Drug-Approvals-in-2023.jpg
628
1200
Rahul Jasuja, PhD
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Rahul Jasuja, PhD2024-01-18 09:36:022024-01-18 16:57:29FDA Drug Approvals in 2023: Major Innovations in Gene Editing and Alzheimer’s TreatmentJan 17, 2024
https://visiblealpha.com/wp-content/uploads/2024/01/The-Visible-Alpha-AI-Monitor_-Companies-to-Watch-in-2024.jpg
628
1200
Melissa Otto, CFA
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Melissa Otto, CFA2024-01-17 13:34:512024-02-27 11:55:09The Visible Alpha AI Monitor: Companies to Watch in 2024Jan 12, 2024
https://visiblealpha.com/wp-content/uploads/2024/01/Strategic-Talent-Management-in-Asset-Management-Navigating-Market-Volatility.jpg
628
1200
Visible Alpha
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Visible Alpha2024-01-12 09:26:502024-01-11 15:27:16Strategic Talent Management in Asset Management: Navigating Market VolatilityNov 28, 2023
https://visiblealpha.com/wp-content/uploads/2023/11/Thoughts-on-the-OpenAI-Microsoft-MSFT-Partnership-Large.jpg
628
1200
Melissa Otto, CFA
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Melissa Otto, CFA2023-11-28 15:03:042024-01-22 13:43:08Thoughts on the OpenAI & Microsoft (MSFT) PartnershipNov 08, 2023
https://visiblealpha.com/wp-content/uploads/2023/11/Novel-Target-for-Ulcerative-Colitis-and-Related-Inflammatory-Diseases-Attracts-Big-Pharma.jpg
628
1200
Rahul Jasuja, PhD
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Rahul Jasuja, PhD2023-11-08 13:56:512024-01-11 09:45:32Novel Target for Ulcerative Colitis and Related Inflammatory Diseases Attracts Big PharmaNov 07, 2023
https://visiblealpha.com/wp-content/uploads/2023/11/BYD-vs.-Tesla-Accentures-Growth-Dip-Solaria-Ramps-Up-Solar.jpg
628
1200
Visible Alpha Research & Innovation Lab
/wp-content/uploads/2019/09/visible-alpha-logo1.png
Visible Alpha Research & Innovation Lab2023-11-07 12:33:582023-12-18 18:39:45BYD vs. Tesla; Accenture’s Growth Dip; Solaria Ramps Up SolarGet it Delivered
Get articles like these including investment research news and insights uncovered using the Visible Alpha platform delivered to your inbox.
Call Us
General Inquiries: +1 646 374 4702
Sales
Americas: +1 646 989-2621
Europe: +44 20 35451032
APAC: +852 3002 0647
Client Support
Americas: +1 646 462 3210
Europe: +44 20 3884 2798
APAC: +852 3002 0649